Evidence map›Paper›PMID 36208817›Full record

Trial reportPreventive medicine2022

Potential effects of nicotine content in cigarettes on use of other substances.

Diann E Gaalema, L Morgan Snell, Jennifer W Tidey, Stacey C Sigmon, Sarah H Heil, Dustin C Lee, Janice Y Bunn, Claire Park, John R Hughes, Stephen T Higgins

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02232737 (Project 3, Study 2), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02232737 phase1 / phase2completednot on this map

Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders

TypeinterventionalSponsorBrown UniversityRan2016 to 2019Enrolled775ConditionsTobacco Use DisorderArmsVery low nicotine content cigarettes
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Diann E GaalemaUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America. Electronic address: diann.gaalema@med.uvm.edu.
L Morgan SnellCenter for Alcohol and Addiction Studies, Brown University, Providence, RI, United States of America.
Jennifer W TideyCenter for Alcohol and Addiction Studies, Brown University, Providence, RI, United States of America.
Stacey C SigmonUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
Sarah H HeilUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
Dustin C LeeBehavioral Pharmacology Research Unit, Johns Hopkins University, Baltimore, MD, United States of America.
Janice Y BunnUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
Claire ParkUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
John R HughesUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
Stephen T HigginsUVM Tobacco Center of Regulatory Science, University of Vermont, Burlington, VT, United States of America.
University of Vermont · USBrown University · USBehavioral Pharma (United States) · US

Funding

VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIAU54DA031659 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LE, CHAP T. · 2011 to 2022
$64.7M
Using wearables and EMA to examine the links between cannabis and depressionP20GM130414 · NIGMS · BROWN UNIVERSITY · PI Jasjit Singh Ahluwalia · 2019 to 2026
$22.0M
Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI KHADANGA, SHERRIE · 2013 to 2022
$21.3M
University of Vermont Tobacco Center of Regulatory ScienceU54DA036114 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2018 to 2022
$19.4M
NIDA NIH HHS U54 DA031659NIDA NIH HHS U54 DA036114NIGMS NIH HHS P20 GM103644NIGMS NIH HHS P20 GM130414
6 · The paper itself

Abstract

A national nicotine reduction policy has the potential to reduce cigarette smoking and associated adverse health impacts among vulnerable populations. However, possible unanticipated adverse effects of reducing nicotine content in cigarettes, such as increasing the use of alcohol or other abused substances, must be examined. The purpose of this study was to evaluate the effects of exposure to varying doses of nicotine in cigarettes on use of other substances. This was a secondary analysis (n = 753) of three simultaneous, multisite, double-blind, randomized-controlled trials examining 12 weeks of exposure to study cigarettes varying in nicotine content (0.4, 2.4, 15.8 mg nicotine/g tobacco) among daily smokers from three vulnerable populations: individuals with affective disorders (n = 251), individuals with opioid use disorder (n = 256), and socioeconomically-disadvantaged women of reproductive age (n = 246). Effect of study cigarette assignment on urine toxicology screens (performed weekly) and responses to drug and alcohol use questionnaires (completed at study weeks 6 and 12) were examined using negative binomial regression, logistic regression, or repeated measures analysis of variance, controlling for sex, age, and menthol status. The most common substances identified using urine toxicology included tetrahydrocannabinol (THC; 44.8%), cocaine (9.2%), benzodiazepine (8.6%), and amphetamines (8.0%), with 57.2% of participants testing positive at least once for substance use (27.3% if excluding THC). No significant main effects of nicotine dose were found on any of the examined outcomes. These results suggest that reducing nicotine content does not systematically increase use of other substances, even among individuals at increased risk of substance use. ClinicalTrials.gov Identifiers: NCT02232737, NCT2250664, NCT2250534.

Indexed as

Smoking CessationTobacco ProductsDronabinolFemaleHumansNicotineSmokersDronabinolNicotineNicotine reductionSubstance useVulnerable populations

Identifiers

PMID36208817
PMCPMC10275576
OpenAlexW4302024765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.